Astrana Health, Inc. (ASTH) Cash Flow Statement

The persistent gap between net income and operating cash flow suggests that reported earnings understate the company's cash-generating ability, likely due to significant non-cash charges such as depreciation, amortization, and stock-based compensation. However, the working capital contribution of $18.9M in 2026Q2 may reflect favorable timing of claims payments or collections, which could reverse. Investors should monitor whether this conversion quality persists as growth normalizes.

The trajectory shows a dramatic improvement in FCF, driven by strong operating cash flow and minimal capex intensity (0.8% of revenue). This suggests that the company's growth is not capital-intensive, and the recent cash build to $429M provides flexibility. However, the volatility in quarterly FCF, including negative quarters in 2024Q4 and 2025Q4, indicates that sustainability is not yet proven, and the improvement may be tied to working capital timing.

The low capex intensity suggests that the company's infrastructure investments are primarily in intangibles and acquisitions, not physical assets. This aligns with the MSO model, where the technology platform and network contracts are the key assets. The modest capex also means that depreciation is not a major cash drain, but the high D&A relative to capex (e.g., $31.0M D&A vs. $7.9M capex in 2026Q2) implies that the company is amortizing acquired intangibles, which may not require cash replacement.

The extreme quarterly swings in working capital, including a $58.9M positive contribution in 2025Q2 and a -$39.2M drag in 2025Q4, suggest that the company's cash flow is heavily influenced by the timing of medical claims payments and capitation receipts. This volatility complicates the assessment of underlying operational performance, as a single quarter's cash flow may not reflect the run-rate. Investors should focus on trailing twelve-month figures to smooth these fluctuations.

The significant cash outflows for acquisitions, particularly the $548.6M in 2025Q3, explain the company's aggressive expansion strategy. Despite the large cash balance of $429M, the company appears to be reinvesting heavily in M&A, which may strain liquidity if acquisition targets underperform. The minimal dividends and buybacks suggest that management sees higher returns from scaling the platform, but the thin net margin of 0.71% raises questions about the return on invested capital from these deals.

The cumulative gap between operating cash flow and net income suggests that the company's earnings quality is high, as cash generation has been consistently stronger than reported profits. However, this divergence may also reflect the heavy use of stock-based compensation (cumulative $104M) and acquisition-related amortization, which are non-cash but still dilute shareholders. The sustainability of this gap depends on whether the company can maintain positive working capital contributions as it scales, which is uncertain given the volatility observed.